海南日报全媒体记者 党朝峰 海南省人大代表、海南远丰食品有限公司董事长徐取俊的朋友圈，弥漫着一股"咖啡味"。 远丰公司工人在加工进口咖啡豆。（受访者供图） （海南日报金江1月21日电） 在澄迈，咖啡豆年加工量在向万吨级迈进。随着自贸港加工增值内销免关税政策红利释放，当地咖啡企 业将扩大产能，发展冻干粉、冷/热萃咖啡液等精深加工产品，致力于打造全豆种、全品类精深加工的咖啡加 工中心。 "抢抓自贸港机遇，助力澄迈咖啡加工产业腾飞！"说起2025年难忘的时刻，徐取俊向记者展示了这则微 信朋友圈。那是去年6月27日，从非洲肯尼亚蒙巴萨港出发，历经近2万公里海上行程，19.2吨货值超110万元 的咖啡豆，抵达位于澄迈县才存社区的远丰公司咖啡加工厂。他介绍，这是澄迈首次以整柜形式自国外进口 的咖啡豆原材料。 "海南自贸港封关运作，给咖啡产业带来了前所未有的机遇。"徐取俊说，远丰公司的故事，折射了海南 自贸港建设喜人的变化，见证着政策落地为产业发展带来的无限可能。 2025年12月18日海南自贸港启动全岛封关当天，以这批咖啡豆为原料深加工后的产品，从澄迈马村港"二 线口岸"销往新疆、青海、广东等地。作为海南自贸港鼓励类产业 ...

低温液态奶、冻干粉等高附加值产品研发有了新进展； ………… 这些天，省人大代表、甘肃元生农牧科技有限公司总经理张希云都在忙着永昌县绵羊奶现代产业园核心 示范区"元生爱特绵羊奶世界之窗"项目。 【代表委员履职故事】 张希云代表：推动产业发展赋能乡村振兴 新甘肃·甘肃日报记者 杜雪琴 绵羊奶精深加工项目加快推进； 不仅如此，张希云还创新构建"龙头企业+村集体经济+农户"利益共享机制，目前已带动61个村集体经 济参与发展，年均分红超500万元；通过良种推广与杂交改良，累计向全省提供优质种公羊3000余只， 完成肉羊改良约5万只，进一步促进农民增收与区域养殖业升级。 过去一年，张希云聚焦破解农业产业融资瓶颈、品牌标准体系建设等方面，多次深入调研，提出具有可 操作性的建议。目前，相关建议已得到有关部门的高度重视与积极响应。 "省十四届人大四次会议即将召开，我将继续立足产业、履职尽责，加快建设智能化精深加工基地，推 动奶绵羊产业高质量发展。"张希云表示，将持续完善联农带农机制，让产业发展成果更广泛惠及人民 群众，真正使奶绵羊产业成为助力乡村振兴的创新典范。 责任编辑：杨晨雨 "我们的项目预计今年11月前后建成投产！"经过 ...

作为长三角地区唯一水和空气质量双双进入全国前十的生态高地，"天生丽质"的生态环境是丽水莲都发 展美丽健康产业的核心优势。当前，大健康产业已成为国家优先发展的战略产业。对莲都而言，将美丽 健康产业作为支柱产业，既是"无中生有"的创新突破，也是实现产业"弯道超车"的关键之举。 多个美妆巨头齐聚莲都 走进浙江茗叶植物科技有限公司，生产线正上演一场充满诗意的变革。包装车间化身为机械臂的舞台 ——机器人精准抓取茶包，码垛机有序叠放成品，从原料入库、检验、上线生产到成品存储，全流程已 实现自动化、智能化。 谈及选择在丽水设立生产基地的原因，公司总经理沈波表示："丽水拥有近60万亩茶叶种植面积，年产 量约5万吨，其种植规模、产量与品质在浙江省均位居前列，这为我们提供了坚实的基础。" 中新网丽水12月26日电(胡丰盛)在浙江省丽水市莲都区，"美丽经济"正蓬勃起势。 作为专业从事茶叶深加工的高新技术企业，该公司植物提取物、抹茶、冻干粉等6条生产线的产能已超 越杭州工厂，不仅能消化大量本地茶叶原料，也有效带动了莲都等地茶农增收。 成功签约珀莱雅、欧诗漫两大美妆巨头；现有美丽健康规上工业企业39家，今年1月至11月，美丽健康 产业 ...

广清纺织服装产业有序转移园管理委员会深度解读了清远的区位交通、空间承载、成本优势以及精准的 时尚产业政策。随后的"广清纺织园项目投产开工仪式"上，宣布广州集美织造有限公司集美纺织科技产 业园项目、广东美续生物科技有限公司生产项目等4个项目动工，清远市汇诚化纤有限公司年产涤纶预 取向丝17万吨项目、戴世拉链（清远）快反中心项目、广东丽彦妆智造生物科技有限公司年产冻干粉1 亿盒、面膜5000万盒和护肤品3000万盒建设项目等5个项目投产，彰显了园区从蓝图规划到项目落地的 坚定步伐与扎实成果。 "AI+样衣共创全场景赋能平台"正式发布，旨在打通从趋势洞察到实体样衣的快 速转化通道。由清城区文化广电旅游体育局呈上的"清城山水间的凤舞清歌"文旅与时尚产业融合发布， 系统介绍了清城的丰富文旅资源，体现了清远传统与时尚共生、文旅与产业共融的可持续发展理念。 来源：环球网 12月19日，2025广东（清远）时尚产业大会暨广东服装大会在清远成功召开，大会以"智汇清远·时尚首 选"为主题，立足广东现代化产业体系建设根基，洞察趋势、链接资源、发布年度观点。 纺织服装产业作为广东省传统优势产业和重要民生产业，清远作为全省产业有序转移 ...

Core Viewpoint - Qianhong Biopharma's stock price has experienced fluctuations, with a year-to-date increase of 44.17%, but a recent decline in the last five trading days by 4.57% [1] Group 1: Company Overview - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province [2] - The company specializes in the research, production, and sales of various pharmaceutical products, including freeze-dried powders, injections, tablets, and raw materials [2] - The main revenue composition is 62.97% from formulations and 36.70% from raw materials [2] Group 2: Financial Performance - For the period from January to September 2025, Qianhong Biopharma achieved a revenue of 1.215 billion yuan, reflecting a year-on-year growth of 0.61%, and a net profit of 383 million yuan, up 23.79% year-on-year [2] - Cumulatively, the company has distributed 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the last three years [3] Group 3: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased to 73,600, with an average of 12,785 circulating shares per person, a decrease of 1.15% from the previous period [2] - The stock has appeared on the "Dragon and Tiger List" seven times this year, with the most recent instance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]

Group 1: Yunnan Coffee Industry - Yunnan coffee has become synonymous with Chinese coffee, with 97.85% of the national planting area, 98.65% of total production, and 98.61% of agricultural output value in 2024 [1][2] - The coffee planting area in Yunnan is expected to grow by 4% year-on-year, with production increasing by 3% in 2024 [1] - The average price of coffee beans is 41.02 yuan per kilogram, up 10.3% year-on-year, and the average price of specialty coffee is 67.37 yuan per kilogram [1] Group 2: Nestlé Financial Performance - Nestlé reported total sales of 65.9 billion Swiss francs for the first nine months of 2025, a decrease of 1.9% year-on-year, but with an organic growth rate of 3.3% [3][4] - The organic growth rate for the third quarter was 4.3%, an improvement from 2.9% in the first half of the year, driven mainly by coffee and confectionery businesses [3] - The company plans to cut approximately 16,000 jobs globally over the next two years, aiming to save 1 billion Swiss francs annually by 2027 [4] Group 3: Bawang Tea Ji Expansion - Bawang Tea Ji opened its highest store globally in Thailand, located on the 74th floor of King Power Mahanakhon, a significant milestone in its Asia-Pacific expansion [5][6] - The brand plans to accelerate its development in Thailand, with five new stores opening this month, bringing the total to 13 by the end of October [6] Group 4: Coffee Machine Standards - A new national standard for home coffee machines has been approved, set to take effect on May 1, 2026, aimed at improving product quality and guiding industry development [8][9] - The standard includes technical requirements for performance, user experience, and environmental indicators, such as noise control and energy consumption [9] Group 5: Tea Industry AI Model - Anhui Agricultural University released the Lu Yu Tea Industry AI model, capable of understanding, reasoning, and generating knowledge related to tea [10] - The model can identify pests and diseases from leaf photos with over 90% accuracy and provides treatment suggestions [10]

Company Overview - Qianhong Biopharma Co., Ltd. is located in Changzhou, Jiangsu Province, established on April 30, 2003, and listed on February 18, 2011. The company specializes in the research, production, and sales of various pharmaceutical products, including lyophilized powder, lyophilized powder injections (including anti-tumor drugs), small-volume injections, tablets, hard capsules, granules, and raw materials [2]. Financial Performance - For the first half of 2025, Qianhong Biopharma achieved operating revenue of 862 million yuan, representing a year-on-year growth of 0.72%. The net profit attributable to the parent company was 258 million yuan, showing a significant year-on-year increase of 41.17% [2]. - The company has distributed a total of 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Qianhong Biopharma's stock price was 9.38 yuan per share, with a market capitalization of 12.005 billion yuan. The stock has increased by 54.20% year-to-date but has seen a decline of 5.44% over the past five trading days and 12.42% over the past 20 days [1]. - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]. Shareholder Information - As of June 30, 2025, Qianhong Biopharma had 72,800 shareholders, an increase of 27.00% from the previous period. The average circulating shares per person decreased by 22.62% to 12,934 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]. Business Segments - The company's main business revenue composition includes 62.97% from formulation series and 36.70% from raw material series, with other contributions at 0.33% [2]. - Qianhong Biopharma operates within the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, and is involved in various concept sectors such as heparin, ursodeoxycholic acid, antigen detection, medical devices, and biomedicine [2].

Group 1 - The stock price of Qianhong Biopharma fell by 2.05% on September 19, closing at 9.54 CNY per share, with a trading volume of 142 million CNY and a turnover rate of 1.56%, resulting in a total market capitalization of 12.209 billion CNY [1] - Year-to-date, Qianhong Biopharma's stock price has increased by 56.83%, but it has seen a decline of 5.36% over the last five trading days and 12.48% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million CNY [1] Group 2 - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province, and specializes in the production and sales of various pharmaceutical products, including lyophilized powder and injections [2] - The company's main business revenue composition includes 62.97% from formulations and 36.70% from raw materials, with other sources contributing 0.33% [2] - As of June 30, 2025, Qianhong Biopharma reported a revenue of 862 million CNY, a year-on-year increase of 0.72%, and a net profit attributable to shareholders of 258 million CNY, reflecting a growth of 41.17% [2] Group 3 - Since its A-share listing, Qianhong Biopharma has distributed a total of 1.862 billion CNY in dividends, with 453 million CNY distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]

Core Insights - The coffee industry in Chengmai County, Hainan, is undergoing a transformation towards a full industrial chain, enhancing the quality and branding of local coffee products [1][2][3] Group 1: Industrial Development - Chengmai County has accelerated the development of its agricultural industry chain, focusing on the entire process from coffee bean to cup, aiming to elevate ordinary coffee to specialty coffee [1][2] - The county has approved 10 enterprises for a duty-free processing policy, with 4 of them being coffee companies, which will significantly reduce raw material costs and enhance market competitiveness [2][3] Group 2: Economic Impact - The first batch of imported coffee beans, weighing 19.2 tons and valued over 1.1 million yuan, marks a significant breakthrough for local enterprises under the Hainan Free Trade Port policy [2] - The coffee industry is expected to drive economic growth by creating job opportunities and increasing income for local farmers, with initiatives like the shared coffee farm benefiting 1,599 households [3] Group 3: Education and Talent Development - The establishment of the Bolan Coffee Academy in Chengmai aims to enhance the training of coffee professionals, with a focus on both enthusiasts and industry entrants [4] - The collaboration between the academy and local coffee enterprises is set to standardize and internationalize the coffee industry in Hainan, providing a robust talent pipeline [4] Group 4: Tourism Integration - The Fushan Coffee Cultural Town is attracting tourists and coffee lovers, offering immersive experiences in coffee production and related activities [5] - Chengmai County plans to innovate a dual-driven model of coffee-themed cultural tourism, integrating agriculture, culture, tourism, sports, and commerce [5]